drugset
drugset / Trial / NCT06652165

Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL

NCT06652165 ↗

Phase 2 Not yet recruiting 66 enrolled Ruijin Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This trial is a prospective, single-center, randomized controlled clinical research. The intention is to evaluate the efficacy and safety of zanubrutinib combined with BEAM as a pretreatment regimen for ASCT in relapsed and refractory DLBCL patients through prospective clinical studies.

Timeline

Start
2024-11-01
Primary completion
2026-11-01
Completion
2028-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanubrutinib Small molecule 160 mg Oral
Background Cytarabine Small molecule 200 mg/m2 Other
Background Etoposide Small molecule 100 mg/m2 Other
Background Melphalan Small molecule 140 mg/m2 Other
Background carmustine Small molecule 300 mg/m2 Other

Indications

diffuse large B-cell lymphoma